BI takes interferon-free Hep C combo into Phase III
This article was originally published in Scrip
Boehringer Ingelheim has begun a pivotal Phase III study of its interferon-free triple combination regimen for hepatitis C, containing its investigational products, the protease inhibitor faldaprevir (BI 201335), and its non-nucleoside polymerase inhibitor BI 207127, together with ribavirin.
You may also be interested in...
Another disappointment for irritable bowel syndrome therapies as Urovant Science’s vibegron fails in a Phase II trial, likely spelling the end for the investigational indication.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.
Another failed study in Duchenne muscular dystrophy spells the end for edasalonexent and possibly the firm.